Niraxx Light Therapeutics Announces Initiation of a Phase 2 Depression Clinical Trial

[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.4.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] “We think the device’s wearability—ability to deliver treatment whenever and wherever—will change the care paradigm for depression.” [/et_pb_text][et_pb_text _builder_version=”4.4.5″ text_font=”Vollkorn||||||||” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone”] Irvine, Calif. — Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced the initiation of a […]